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Abstract
Emphysema is recognized as the component of chronic obstructive airways disease that
is responsible for airways obstruction. Different patterns of emphysema are, however,
recognized, suggesting possible different pathogenetic processes within the lung. This,
coupled with the associated idea of susceptibility factors to the development of emphysema,
has led to studies of genes that may be involved in the defence of the lung from proteolytic
and oxidative damage. These studies have been driven by the goal of finding a treatment for
emphysema, but appear to have lost sight of the fundamental remodelling of the lung that
has occurred in patients with emphysema and the fact that it is not a single morphological
entity. Copyright  2004 John Wiley & Sons, Ltd.
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Historical background
Emphysema, as a major component of chronic obstruc-
tive pulmonary disease (COPD), is a significant cause
of morbidity and mortality, although perhaps only
a quarter of smokers develop clinically significant
emphysema [1]. The presence and severity of emphy-
sema in patients with COPD, whether assessed micro-
scopically or by computed tomography (CT), has been
shown to correlate with decreased gas transfer and the
fall in FEV1 [2] that characterizes this condition and
it is believed to be the pathological cause of the fixed
irreversible airways obstruction seen in these individ-
uals due to loss of alveolar wall attachments to small
bronchioles in the distal lung [3,4].
Emphysema was first defined as ‘a condition of the
lung characterized by an increase beyond the normal
in size of the airspaces distal to the terminal bronchi-
ole either from dilation or from destruction of their
walls’ [5]. This original definition did not distinguish
between over-inflation and the disruption of the lung
architecture, which occurs in smoking-related emphy-
sema. In 1962, the definition suggested was ‘a condi-
tion of the lung characterized by abnormal, permanent
enlargement of airspaces distal to the terminal bronchi-
oli accompanied by destruction of their walls’ [6]. This
was further modified in 1985, by adding ‘accompa-
nied by destruction of their walls and without obvious
fibrosis’ [7].
Whilst useful, these definitions are actually an over-
simplification. To fulfil the definition of emphysema,
three points must be taken into account, ie the size
of airspace, evidence for a destructive process, and an
assessment that fibrosis is minimal [8]. None of the
definitions was accompanied by criteria that allowed
the concept of ‘normal airspace size’ to be defined.
Similarly, in the 1985 definition, the term ‘without
obvious fibrosis’ is clearly a conceptual statement and
may give rise to problems in relationship to the pres-
ence of smoking-related fibrosis in lungs where both
inflammatory cells and fibrosis are frequently encoun-
tered. Furthermore, changes occur in ageing lungs [9]
that are qualitatively similar to emphysema in smok-
ers, suggesting either that clinically significant emphy-
sema is at the severe end of normal tissue loss through
ageing (similar to bone and neurones) or that ageing-
related loss of lung tissue is the benign end of a spec-
trum of disease resulting from environmental exposure
to toxic chemicals [10].
The pathological appearances of the lungs in
patients with COPD are well described in pathology
textbooks [11] and for several decades emphysema
has essentially been a pathologist’s territory, with
great effort being directed towards classification into
anatomic types. Thus, centriacinar emphysema (CAE)
(synonyms preacinar, proximal acinar, centrilobular)
was envisaged as the result of immediate injury to res-
piratory bronchioles and adjacent tissues, essentially
an active destructive process. The abnormal airspaces
are found in association with respiratory bronchioles,
though in more severe cases virtually the whole acinar
unit may be involved. In most cases of CAE, there is a
distinct distribution with gradation of severity from the
apex of the lung towards the base. Panacinar emphy-
sema (PAE) (synonyms periacinar, distal acinar), by
contrast, is a more diffuse process, at least in its early
stages, characterized by remodelling of the lung, loss
of elastic recoil, and increased capacity. Abnormally
large airspaces are found evenly distributed across the
acinar unit. Adjacent acinar units are usually involved
to a similar degree, giving a confluent appearance to
the cut surface of the lung, with extensive areas being
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involved. There is no obvious macroscopic pattern to
the distribution of the disease in the lung. In parasep-
tal emphysema, the abnormal airspaces run along the
edge of the acinar unit, but only where it abuts against
a fixed structure such as the pleura, a vessel or a
septum. Two other types of emphysematous changes
were described, scar emphysema (synonym irregular),
where the emphysematous spaces are found around the
margins of a scar, and bullous emphysema, in which
areas of emphysema are locally overdistended to pro-
duce a lesion which, if superficial, stands proud of the
pleural surface [12].
These differences, with the associated implication
that the aetiology and pathogenesis may differ, have
been largely forgotten by researchers because no
reliable functional or clinically significant differences
have been identified that correlate with structure.
Patients with COPD do vary in their clinical behaviour
and patterns of respiratory failure, but no relationship
between these and the pattern of emphysema present
has been demonstrable [13]. Nor has any link between
any of the recognized risk factors for emphysema and
the pattern of disease been identified. Thus, the term
‘emphysema’ has passed into common usage as if it
is a homogeneous disease.
Possible aetiology and pathogenesis
The absence of any association with risk factors or
clinical features does, however, raise the possibility
that the development of emphysema and its different
pathological patterns could be the result of interaction
between external risk factors and intrinsic host suscep-
tibility factors. The concept of susceptibility factors
was first suggested by the observation that emphy-
sema occurs in patients with α1-anti-trypsin (α1-AT)
deficiency [14] and that this was exacerbated by con-
comitant smoking. α1-AT is a major plasma inhibitor
of proteolytic enzymes and since such enzymes can
induce experimental ‘emphysema’ in animal models,
it seemed plausable that the association of α-protease
deficiency with emphysema [15] was the result of
unopposed proteolytic activity in the lung giving rise
to the generally accepted protease/anti-protease theory
of injury. This was further refined when the enzyme
elastin was also found to have the potential to cause
experimental ‘emphysema’. Thus, the protease/anti-
protease theory was evolved into the elastase/anti-
elastase theory of the pathogenesis of emphysema,
with neutrophil elastase (NE) being the major enzyme
implicated [16–19]. Macrophages are another poten-
tial source of protease enzymes and are commonly
seen in a centriacinar position in smokers, although
not always concomitant with emphysema [20]. It has
been postulated that these cells, possibly regulated
by T-lymphocytes, release macrophage serine elastase,
which is much more efficient in degrading lung inter-
stitium, and that this may be more important [21].
Whilst clearly applicable to animal models and
the human situation in α1-AT deficiency, this the-
ory has not been fully substantiated for the generality
of human emphysema. Refinement of the theory has
therefore occurred, in particular recognizing the role
of oxidants. Each puff of cigarette smoke generates
1015 –1017 free radicals [22,23]. In addition, oxida-
tive metabolism of other compounds in both bron-
chiolar and alveolar epithelium, especially by smoke-
inducible cytochrome p450’s, generates even more
radicals [23,24]. Oxygen free radicals damage many
structures and cause immediate neutrophilic infiltra-
tion, as well as directly inhibiting protease inhibitors
[25]. In addition, nicotine may prolong the life span
of neutrophils and thus potentiate lung damage [26].
So, the theory of protease/anti-protease imbalance has
been modified by adding the effects of oxidants and
possibly by invoking different elements of both innate
and adaptive immunity.
There still remains, however, the question of why
only a proportion of smokers develop emphysema.
Within the extracellular fluid in the lung, there is a bias
towards the quenching of oxidants and free radicals.
Uric acid, reduced glutathione, ascorbate, sacrificial
sulphoproteins which can be oxidized and discarded,
extracellular superoxide dismutase (SOD3), catalase,
and glutathione peroxidase all serve to protect the
epithelial lining. Within the cells, in addition, there are
protective antioxidant enzymes that by conjugation,
cleavage of peroxides or deapoxidation remove toxic
species [27]. Could differences in this antioxidant
protection be important in determining whether or not
emphysema occurs?
Oxidative stress: the balancing act
A number of enzymes involved in the activation,
metabolism, and detoxification of cigarette compo-
nents are polymorphic. In some situations, this geno-
typic variation is reflected by a difference in functional
enzyme activity. The range of enzymes is large, sub-
strate specificity frequently overlaps, and there may be
considerable redundancy between different enzymes.
Cytochrome p450 1A1 (CYP1A1) has a rare vari-
ant (<5%) which is thought to result in increased
inducibility and hence activity of the enzyme. CYP1A1
metabolizes many components of cigarette smoke to
active radicals and the enzyme is itself induced by
cigarette smoke [28]. Several studies have linked the
rare variant of CYP1A1 genotype to increased sus-
ceptibility to lung cancer in smokers. However, these
studies highlight one of the problems inherent in stud-
ies of emphysema and lung cancer, namely that both
diseases may co-exist. A similar study repeated in a
UK population where the presence of emphysema and
cancer was taken into consideration revealed a very
small association between CYP1A1 genotype and sus-
ceptibility to emphysema, but not to cancer. However,
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the relative risk was small and of doubtful significance
in the population as a whole [29].
Similarly, a detoxification enzyme, glutathione S-
transferase M1 (GSTM1), a member of a detoxification
family conjugating free radical species to reduce glu-
tathione and also directly engaged in protection against
peroxidation injury, is polymorphic [30]. Approxi-
mately 50% of the population have a deletion of part
of or the entire gene at both alleles and are therefore
GSTM1 null [31]. Again, several studies have associ-
ated GSTM1 null with increased risk of lung cancer,
but once again if the presence or absence of emphy-
sema is taken into account, the association is with
emphysema rather than lung cancer [32]. Although
GSTM1 is expressed in lung, it is present at a higher
concentration in liver, raising the possibility that much
injury inflicted on the lung by cigarette smoke may be
the result of systemic metabolism.
Microsomal epoxide hydrolase (mEPHX) is an
enzyme involved in the metabolism of highly reactive
epoxide intermediates. Four distinct mEPHX alleles
exist which arise because of the presence of two point
mutations in the gene. An exon 3 T-to-C mutation
changes Tyr 113 to His, reducing enzyme activity by
at least 50% (slow allele). The second, an A-to-G
transition mutation in exon 4 of the gene, changes
His 139 to Arg, producing an enzyme with a puta-
tive increase in activity of at least 25% (fast allele).
The wild-type allele is characterized by the absence of
these two changes, but the presence of both mutations
in a rare mEPHX allele produces a hydrolase with
normal activity. It has been demonstrated that there
is an association between genetically defined poly-
morphisms in mEPHX activity and susceptibility to
COPD and emphysema and this suggests that highly
reactive epoxide intermediates may play a role in the
initiation and progression of the character tissue abnor-
malities seen in emphysema [33]. Polymorphisms of
the mEPHX gene may be an important risk factor in
lung disease associated with oxidative stress, consis-
tent with the direct effects of cigarette smoke compo-
nents.
We appear to have come some distance in under-
standing the external environmental factors that lead to
emphysema and possible genetic risk factors that may
influence who develops it. One of the challenges, how-
ever, in further understanding the role and interaction
of these factors will be in explaining the divergent pat-
terns of lung remodelling that occur in these patients
which, as described, is not homogeneous.
Implications for treatment
Much of the interest in this type of research in the last
few years has been driven by an interest in devel-
oping strategies or agents that might interfere with
these proposed pathogenetic mechanisms. So, what are
the implications for the treatment of emphysema from
this research? What is clear is that the most effec-
tive preventative measure to reduce the incidence of
emphysema is for people not to smoke cigarettes, or
to stop if they do smoke [1]. The disease is slowly
progressive and there is evidence that the rate of loss
of lung tissue reduces to ‘normal levels’ if cigarette
smoking is stopped [34]. It remains unclear, however,
whether approaches based on modulating inflamma-
tion or modulating the oxidant/antioxidant balance will
be feasible.
Techniques under evaluation include the use of
exogenously administered pharmacological agents, but
also gene therapy with the aim of local production
of anti-elastase/elastase inhibitors in the treated lung
[35–39]. There still remains the problem, so far
ignored, that the pathological basis of emphysema
and fixed airways obstruction is the result of lung
remodelling with the loss of alveolar walls and support
of the small peripheral bronchioles. All the proposed
treatments are, at most, likely to prevent or modify
future remodelling in patients who continue to smoke,
but it would seem unlikely that even with stem cell
therapy (for discussion see ref 40) lost alveolar tissue
will be restored. In many respects, a more realistic,
simpler, and cheaper alternative for the vast majority
of patients with emphysema is to prevent disease
progression by smoking cessation. The alternative
approach, which appears to be where we may be
heading, is the development of agents which at best
will protect the lung from damage, whilst permitting
the patient to continue smoking!
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